2015
DOI: 10.1016/j.bjane.2014.11.002
|View full text |Cite
|
Sign up to set email alerts
|

Effect of low dose dexmedetomidine premedication on propofol consumption in geriatric end stage renal disease patients

Abstract: Dexmedetomidine premedication lowers intraoperative propofol consumption to maintain targeted level of sedation. Therefore low dose dexmedetomidine premedication in addition to propofol infusion might be an alternative in geriatric patients with end-stage renal disease for sedation.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 25 publications
0
4
0
Order By: Relevance
“…In previous studies applying single‐ or initial‐dose dexmedetomidine sedation in elderly patients, bradycardia and hypotension were the most common side‐effects, and occurred more frequently with dexmedetomidine doses exceeding 0.5 μg/kg 8, 18, 19, 20, 21. Although a previous study reported that maintenance doses of up to 10 μg/kg per hour were tolerated,27 without producing hypotension or bradycardia, when used as a total intravenous anesthetic agent in certain patients, there are other case reports in which the use of dexmedetomidine in elderly patients was associated with the occurrence of severe bradycardia or hypotension,27, 28 sometimes even progressing to asystole.…”
Section: Discussionmentioning
confidence: 97%
See 1 more Smart Citation
“…In previous studies applying single‐ or initial‐dose dexmedetomidine sedation in elderly patients, bradycardia and hypotension were the most common side‐effects, and occurred more frequently with dexmedetomidine doses exceeding 0.5 μg/kg 8, 18, 19, 20, 21. Although a previous study reported that maintenance doses of up to 10 μg/kg per hour were tolerated,27 without producing hypotension or bradycardia, when used as a total intravenous anesthetic agent in certain patients, there are other case reports in which the use of dexmedetomidine in elderly patients was associated with the occurrence of severe bradycardia or hypotension,27, 28 sometimes even progressing to asystole.…”
Section: Discussionmentioning
confidence: 97%
“…Previous studies have described administration of single‐ or initial‐dose dexmedetomidine in elderly patients sedation 8, 18, 19, 20, 21. Generally, doses ranging from 0.5–1.0 μg/kg delivered as a 10‐min infusion were associated with excessive sedation, bradycardia, hypotension, desaturation, or delayed recovery.…”
Section: Discussionmentioning
confidence: 99%
“…DEX is highly selective α 2 -adrenergic agonist, and is widely used for anxiolysis, sedation, and analgesia. 4 , 5 Recently, studies have demonstrated the protective benefits of DEX, which are exerted through its anti-inflammatory properties. 6 9 Administration of DEX could alleviate systemic inflammation in animals through stabilization of the sympathetic nervous system.…”
Section: Discussionmentioning
confidence: 99%
“…Dexmedetomidine (DEX) is a highly selective α 2 -adrenergic agonist that has demonstrated sedative, analgesic, and anxiolytic effects. 4 , 5 Beyond these benefits, emerging data show that the medication also exhibits anti-inflammatory properties. 6 9 Treatment with DEX has been shown to attenuate the release of cytokines in cells stimulated by endotoxin in a dose-dependent manner in in vitro studies.…”
Section: Introductionmentioning
confidence: 99%